Efinaconazole

Efinaconazole
Clinical data
Trade names	Jublia, Clenafin
AHFS/Drugs.com	Monograph
MedlinePlus	a614050
License data	US DailyMed: Efinaconazole; US FDA: Efinaconazole;
Routes of; administration	Topical
ATC code	D01AC19 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: ℞-only;
Identifiers
	IUPAC name (2R,3R)-2-(2,4-Difluorophenyl)-3-(4-methylene-1-piperidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol;
CAS Number	164650-44-6;
PubChem CID	489181;
DrugBank	DB09040;
ChemSpider	428538;
UNII	J82SB7FXWB;
KEGG	D10021;
ChEBI	CHEBI:82718;
ChEMBL	ChEMBL2103877;
CompTox Dashboard (EPA)	DTXSID40167787 ;
ECHA InfoCard	100.245.862
Chemical and physical data
Formula	C18H22F2N4O
Molar mass	348.398 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@H]([C@](CN1C=NC=N1)(C2=C(C=C(C=C2)F)F)O)N3CCC(=C)CC3;
	InChI InChI=1S/C18H22F2N4O/c1-13-5-7-23(8-6-13)14(2)18(25,10-24-12-21-11-22-24)16-4-3-15(19)9-17(16)20/h3-4,9,11-12,14,25H,1,5-8,10H2,2H3/t14-,18-/m1/s1; Key:NFEZZTICAUWDHU-RDTXWAMCSA-N;

Efinaconazole, sold under the brand name Jublia and Clenafin among others, is a triazole antifungal compound discovered by Kaken Pharmaceutical, indicated for the treatment of onychomycosis, a fungal infection of the nail. Since it has low binding affinity with keratin, the main component of nails, it has superior nail-penetrating properties. It is approved for use in the United States, Canada, Japan and certain European countries as a 10% topical solution.

Efinaconazole acts as a 14α-demethylase inhibitor.